Ingrid Asp Psoriasis Research Center, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Unit of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
J Am Acad Dermatol. 2014 Jun;70(6):1067-75. doi: 10.1016/j.jaad.2013.12.044. Epub 2014 Mar 20.
Psoriasis is associated with a systemic inflammation and an increased frequency of the metabolic syndrome, both of which are believed to link psoriasis to an increased risk of cardiovascular disease.
The study aimed to investigate the systemic expression of markers of cardiovascular risk and determine their response to ultraviolet B therapy and treatment with the tumor necrosis factor-alfa inhibitor, etanercept.
Six markers of cardiovascular risk were measured in 28 patients with psoriasis and 28 control subjects.
Five of the 6 investigated markers were elevated in patients with psoriasis. Four of these correlated to the body mass index and waist-hip ratio, suggesting a link to the metabolic syndrome. Total plasminogen activator inhibitor-1 remained elevated independently of these factors. The levels of the investigated risk markers decreased considerably after tumor necrosis factor-alfa inhibitor treatment but remained unaffected by ultraviolet therapy.
A relatively limited study population and nonrandomization are limitations.
These findings suggest that the choice of treatment in psoriasis may influence the cardiovascular risk in patients with psoriasis and the metabolic syndrome.
银屑病与全身炎症和代谢综合征的发生频率增加有关，而这两者都被认为与心血管疾病风险增加有关。
本研究旨在探讨心血管风险标志物的全身表达，并确定它们对紫外线 B 治疗和肿瘤坏死因子-α抑制剂依那西普治疗的反应。
对 28 例银屑病患者和 28 例对照者进行了 6 种心血管风险标志物的测量。
银屑病患者有 5 种被调查的标志物升高。其中 4 种与体重指数和腰臀比相关，提示与代谢综合征有关。总纤溶酶原激活物抑制剂-1升高与这些因素无关。肿瘤坏死因子-α抑制剂治疗后，调查的风险标志物水平显著降低，但紫外线治疗对其无影响。
研究人群相对有限且未随机分组是其局限性。
这些发现表明，银屑病患者的治疗选择可能会影响其心血管风险和代谢综合征。
